Key variants such as GLP1R rs6923761, GIPR rs1800437, and genes affecting NAD-dependent pathways (like SIRT1 and NAMPT) can reveal whether your genetic profile supports complementary NAD therapy alongside tirzepatide
Overall effect: Improved glycemic control through increased insulin secretion, decreased glucagon secretion, reduced hepatic glucose production, and delayed gastric emptying
Schedule: Subcutaneous injections 3 times weekly (Mon/Wed/Fri) for 816 weeks
FAQs Even after digging into the science behind NAD+ vs Glutathione, it is normal to have a few practical questions
Regarding the dosage of LC, Musazadeh et al
In addition, the FDA also must ensure the integrity of the drug approval process and, thus, does not permit 503B compounders to market versions of compounded products that are essentially duplicate copies of approved drug products unless there is a documented patient-specific need for an alternate form of the compounded product